NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries

DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) is setting its sights on a substantially larger international clinical effort, outlining plans for a trial targeting approximately 500 patients across 30 hospitals in three countries during a discussion on Health Uncensored with Dr. Drew, on Fox Business Network.

The proposed expansion brings fresh attention to NeOnc’s effort to address one of brain cancer treatment’s toughest challenges: delivering potential therapies into the brain. The discussion connected the scale of the company’s ambitions with its investigational treatment strategy, early clinical observations and the patients whose experiences give that work urgency.

Five developments stood out.

The planned approximately 500-patient trial would take NeOnc’s research into a substantially larger clinical setting, extending evaluation beyond the smaller patient groups discussed in its early clinical experience.

With around 30 hospitals envisioned across three countries, the proposed study represents a significant development goal for the company. These figures describe planned participation, rather than completed enrollment.

The brain’s natural defenses can also stand in the way of treatment. The blood-brain barrier protects the brain, but it can prevent potential therapies from reaching tumors.

NeOnc’s investigational NEO100 program approaches that challenge through intranasal administration, a delivery method designed to carry therapy through the nose to the brain while bypassing the blood-brain barrier. The approach makes drug delivery itself a central part of the company’s treatment strategy.

The discussion also highlighted NeOnc’s precision medicine approach: identifying molecular characteristics that may help determine which patients could respond to treatment.

Researchers discussed IDH mutations and the evaluation of NEO100 in patients with these tumor characteristics. By pairing targeted patient selection with intranasal delivery, NeOnc is investigating both how a therapy reaches the brain and whom it may help.

The discussion drew attention to earlier clinical observations, including a reported 24% remission figure. In its December 2025 clinical update, NeOnc described significant radiographic remission in six of 25 patients across its combined clinical and compassionate-use experience.

Those findings give the larger research effort a meaningful foundation to investigate. They remain preliminary observations from a small, nonrandomized population and do not establish treatment effectiveness or predict individual outcomes.

The patient stories brought the purpose of the research into focus. One patient described reaching two years on therapy and reported tolerating treatment without reactions and when Dr Drew asked her doctor if the tumor was staying or regressing, Dr. Wallace responded, “We can’t see it, actually, at this moment.”

Physicians spoke about what additional time could mean: another birthday, another anniversary and more moments with loved ones. These individual experiences cannot establish how other patients will respond, but they underscore why further research matters.

In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a2f0b9e4-f888-425c-9ee5-6a6c9975ec07